|
 |
MylotargThis page contains recent news articles, when available, and an overview of Mylotarg but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Mylotarg (when available) Used for the treatment of acute myeloid leukemia (AML), mylotarg binds to the CD33 antigen, which is expressed on the surface of leukemic cells in more than 80% of patients with AML. The CD33 antigen is not expressed on pluripotent hematopoietic stem cells or nonhematopoietic cells. This gives mylotarg the selectivity needed to target leukemic cells. For treatment of acute myeloid leukemia Mechanism Of Action: Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death. News Articles on Gemtuzumab ozogamicin Minimal Residual Disease-directed Therapy Improves Outcomes of Childhood AML - Dec 23, 2009 A second induction course consisted of low-dose cytarabine with or without Mylotarg® (gemtuzumab). Mylotarg was given to MRD-positive patients. ... Cancer Consultants Pfizer gives notice of staff cuts at former Wyeth plant - Dec 9, 2009 The Pearl River site manufactures the Prevnar infant pneumococcal vaccine, Mylotarg (gemtuzumab ozogamicin), which is used to treat a form of acute myeloid ... Pharmafocus Breast Cancer “Smart Bombâ€? Drug From Roche, ImmunoGen Passes Important Trial - Dec 12, 2009 One drug designed to work this way, Wyeth's gemtuzumab ozogamicin (Mylotarg), is approved by the FDA, but it has never gained much widespread use or ... Xconomy Research and Markets: Stakeholder Insight: Acute Leukemias - Reaching the ... - Oct 28, 2009 ...in AML is Mylotarg (gemtuzumab ozogamicin; Wyeth) but its use is limited to elderly, relapsed patients who are not candidates for other chemotherapy. ... Reuters Wyeth Wins European Nod for Torisel, Not for Mylotarg - Sep 20, 2007 By Lisa Rapaport. Sept. 20 (Bloomberg) -- Wyeth won a European regulatory panel recommendation for clearance of its kidney-cancer treatment Torisel, ... Bloomberg Gemtuzumab ozogamicin (Mylotarg ® ) as single-agent treatment for... - Aug 4, 2005 Correspondence: Professor S Amadori, Department of Hematology, University 'Tor Vergata', St Eugenio Hospital, P.le dell'Umanesimo, 10, 00144 Rome, Italy. ... Nature.com Mylotarg® May Decrease Relapse Rate in Patients with Newly … - Dec 9, 2006 Researchers affiliated with the MRC AML 15 trial have reported that the addition of Mylotarg (gemtuzumab ozogamicin) to one of three different induction ... Cancer Consultants Acute myelogenous leukemia (AML) - Jul 11, 2008 One monoclonal antibody used as a biological therapy in AML is gemtuzumab ozogamicin (Mylotarg). This drug carries a chemical toxin that releases when it ... MayoClinic.com Increased Use of Wyeth's Mylotarg and Launches of New Drugs Will More... - Oct 16, 2006 WALTHAM, Mass., Oct. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, ... $4.95 - PR Newswire - ECNext ASH: Mylotarg Boosts AML Disease-Free Survival - Dec 12, 2006 By Neil Osterweil, Senior Associate Editor, MedPage Today. ORLANDO, Dec. 12 -- Antibody-directed therapy added to induction chemotherapy for acute myeloid ... MedPage Today Cancer Therapy; Administration of mylotarg yielded high rate of... - Oct 4, 2005 ..."We have used the dose of 9 mg/m2 of mylotarg 4 days after the beginning of a ... Although the dose of mylotarg given in combination with chemotherapy was ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones European Committee Issues Positive Opinion On Wyeth's TORISEL For … - Oct 1, 2007 ..."We believe that MYLOTARG is an important drug treatment for acute myeloid leukemia, and we will continue to work with the CHMP to address the committee's ... Medical News Today - Medical News Today (press release) Press Release: Increased Use of Wyeth's Mylotarg and Launches of New ... - Oct 16, 2006 Increased Use of Wyeth's Mylotarg and Launches of New Drugs Will More Than Double the Acute Myeloid Leukemia Market By 2015. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research What if the Leukemia Doesn't Respond or Comes Back After Treatment? (... - Aug 3, 2007 Gemtuzumab ozogamicin (Mylotarg) may also be an option, particularly in older ... Gemtuzumab ozogamicin (Mylotarg) has been used in some patients who have ... ACS News Center Japanese OK for Wyeth's Mylotarg.(Wyeth Lederle Japan Ltd.)(Brief … - Aug 8, 2005 Wyeth Japan says that it has obtained approval for Mylotarg, ... Mylotarg is a calicheamicin-conjugated, humanized anti-CD33 monoclonal antibody indicated ... $4.95 - Pharma Marketletter - ECNext Leukemia; Two Genasense Injection clinical study results reported - Jan 8, 2005 A phase 2 trial of Genasense plus Mylotarg (gemtuzumab ozogamicin; Wyeth) showed ... The first trial was a multicenter study of Genasense plus Mylotarg in ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Gemtuzumab Ozogamicin Boosts Effects of Arsenic Trioxide in High-Risk... - May 22, 2007 Therefore, Dr. Sekeres and colleagues conducted a trial in which they evaluated a combination arsenic trioxide and gemtuzumab ozogamicin (Mylotarg®) in ... DG News PDL Grants Patent Licenses to Merck for Humanized Antibodies Against ... - Jan 3, 2006 Synagis is a registered US trademark of MedImmune, Inc. Mylotarg is a registered US trademark of Wyeth. CONTACT: Ami Knoefler, Senior Director, ... RedOrbit Treatment of Children With Acute Myelogenous Leukemia - Aug 19, 2007 Mylotarg is a chemotherapy drug attached to a manmade antibody. The antibody is designed to bring the chemotherapy directly to the AML cells. ... ACS News Center Wyeth up on completing Japan unit buyout - Apr 3, 2007 Wyeth KK sells products such as Enbrel for the treatment of rheumatoid arthritis and psoriasis in Japan, as well as Mylotarg, a bone marrow cancer treatment ... ABCmoney.co.uk CD33 is expressed on plasma cells of a significant number of myeloma ... - Sep 15, 2005 These results support the idea to use Mylotarg ® in the treatment of ... Thus, the use of Mylotarg ® might also target the myeloma stem cell population. ... Nature.com Antibody drug conjugates: a marriage of biologics and small molecules:... - Jun 1, 2008 Wyeth's (Madison, NJ) Mylotarg is the only ADC approved by the US Food and Drug ... Mylotarg consists of a recombinant humanized IgG4 kappa antibody ... $9.94 - Pharmaceutical Technology - Alacra Store Funding denied for life-saving drugs - Dec 21, 2006 Janis added: "We probably wouldn't have been asking for Mylotarg if he had ... Mrs Main said this week: "The consultant feels Mylotarg offers him a good ... Advertiser 24 Therapeutic research in untreated acute promyelocytic leukemia - Apr 21, 2005 Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic ... Gemtuzumab ozogamicin (mylotarg) as a single agent for molecularly relapsed ... Nature.com Leukemia; Two Genasense Injection clinical study results reported - Jan 3, 2005 A phase 2 trial of Genasense plus Mylotarg (gemtuzumab ozogamicin; Wyeth) showed ... The first trial was a multicenter study of Genasense plus Mylotarg in ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones Cancer Treatment; Research from the United States, Austria and France... - May 15, 2006 Study 3: Administration of mylotarg 4 days after beginning a chemotherapy ... "We have used the dose of 9 mg/m2 of mylotarg 4 days after the beginning of a ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Treatment gives Brett his life back - Jun 7, 2007 And now, following a bone-marrow transplant as a direct result of Mylotarg putting his leukaemia into remission, Brett has had the wonderful news that he is ... Advertiser 24 Leukemia; Two Genasense Injection clinical study results reported - Jan 4, 2005 A phase 2 trial of Genasense plus Mylotarg (gemtuzumab ozogamicin; Wyeth) showed ... The first trial was a multicenter study of Genasense plus Mylotarg in ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones FDA to Discuss the Efficacy of Tipifarnib in Acute Myeloid Leukemia - May 5, 2005 During ODAC's 2000 review of Mylotarg, committee members considered the response ... Zarnestra would be indicated for a different population than Mylotarg, ... RxPG NEWS Press Release: European Committee Issues Positive Opinion on Wyeth's ... - Sep 20, 2007 European Committee Issues Negative Opinion on MYLOTARG(R) for Acute Myeloid ... "We believe that MYLOTARG is an important drug treatment for acute myeloid ... Pay-Per-View - PR Newswire Europe - HighBeam Research New drug brings hope for Brett - Feb 8, 2007 Boat-builder Brett Dingwall, aged 56, of Drop Lane, Bricket Wood, has emerged from a course of treatment with the drug Mylotarg with his leukaemia in ... Advertiser 24 Cancer Therapy; Data advance knowledge in cancer therapy research - Nov 29, 2005 Study 1: Administration of mylotarg 4 days after beginning a chemotherapy ... "We have used the dose of 9 mg/m2 of mylotarg 4 days after the beginning of a ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant … - May 26, 2005 Experience with gemtuzumab ozogamycin ('mylotarg') and all-trans retinoic ... Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed ... Nature.com Leukaemia man wins bid for drug - Jan 11, 2007 Janis said this week that her husband had been given Mylotarg in conjunction ... His family will never know if he would have needed Mylotarg had he been ... Advertiser 24 Incidence and management of hepatic venoocclusive disease in 237 … - Oct 23, 2006 Twelve patients had oral busulphan as part of conditioning and one patient received mylotarg 32 days post transplant. Six patients had a previous HSCT (five ... Nature.com Medarex Toxin Conjugate Webcast - Final. - Sep 27, 2005 That is the small molecule component of Mylotarg. And Mylotarg failures in the clinic have been correlated with expression of multidrug resistance pumps, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Press Release: CuraGen and TopoTarget Initiate Phase I/II Clinical... - Aug 28, 2007 Article: Increased Use of Wyeth's Mylotarg and Launches of New Drugs Will ... PR Newswire; October 16, 2006 ; 700+ words ... ... double the market to treat ... Pay-Per-View - PR Newswire - HighBeam Research Why Clean Tech Is Taking Biotech's Shine - Oct 7, 2008 He had a hand in creating cancer and metabolic disease drugs Mylotarg, Symlin, Byetta, and Lorcaserin. But when he decided to start his own company based on ... BusinessWeek Nuclear Localizing Sequences: An Innovative Way to Improve Targeted … - Jan 18, 2006 HuM195 is in current clinical use as Mylotarg (Wyeth-Ayerst; HuM195 conjugated with ... Despite the enticing ability to target leukemia cells with Mylotarg, ... Journal of Nuclear Medicine (subscriptio... Gemtuzumab therapy for isolated extramedullary AML relapse following ... - Feb 27, 2007 ...(2002) Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic ... Nature.com Coding polymorphisms in CD33 and response to gemtuzumab … - Jul 10, 2008 In the United States, GO is formulated and marketed as Mylotarg and is approved as monotherapy for patients >60 years of age with a first relapse of AML who ... Nature.com SAFC bets on drug conjugates with new manufacturing suite - Oct 3, 2007 Mylotarg was approved in 2000 to treat acute myeloid leukaemia. Sales of the drug are currently around $20m (€14.7m) and could reach $60m by 2010, ... OutSourcing-Pharma.com Leukemia burden delays lymphocyte and platelet recovery after allo... - Nov 17, 2008 ...melphalan dose (100, 140 or 180 mg/m 2 ), and the use of gemtuzumab (Mylotarg) or antithymocyte globulin in the conditioning regimen. ... Nature.com Optimizing bioconjugation processes: this article discusses a number... - May 1, 2007 ...(1,2) The approval of the chemotherapy agent Mylotarg ... The first FDA-licensed immunotherapy conjugate Mylotarg has a highly non-Poisson distribution, ... Free with registration - Pharmaceutical Technology Europe - AccessMyLibrary.com Small biotechs forced to turn attention to shareholders - Nov 17, 2008 Herceptin, Xolair, Raptiva and Lucentis, MedImmune Inc.'s Synagis, Elan Pharmaceuticals Inc.'s Tysabri and Wyeth Pharmaceutical's Mylotarg. ... Bizjournals.com Active Older Patients Demanding Surgery | Article from AP Online | … - May 8, 2005 ...that many ... pledge to continue studying Mylotarg's effect. Studies in younger patients continue, too. Wyeth-Ayerst said Mylotarg will be available ... ... Pay-Per-View - AP Online - HighBeam Research T cell antibodies to treat diabetes - Apr 10, 2007 Mylotarg is an anticancer drug composed of an antibody attached to a toxic antitumor antibiotic. JDRF also supports other industry diabetes research, ... DrugResearcher.com PDL names McLaughlin as CEO-to-be - Nov 10, 2008 Herceptin, Xolair, Raptiva and Lucentis, MedImmune Inc.'s Synagis, Elan Pharmaceutical Inc.'s Tysabri and Wyeth Pharmaceutical's (NYSE: WYE) Mylotarg. ... Bizjournals.com PDL's Potent Pick-Me-Up - Feb 27, 2006 PDL also receives royalties from Wyeth (WYE; $49.14; 4 STARS) on sales of Mylotarg for the treatment of acute myeloid leukemia. It also receives royalties ... BusinessWeek Lonza plans to commercially produce emerging class of drugs - May 10, 2007 Mylotarg was approved in 2000 to treat acute myeloid leukaemia. Sales of the drug are currently around $20m (€14.7m) and could reach $60m by 2010, ... In-PharmaTechnologist.com The nano state is here - Feb 25, 2006 The first nanomedicine of this sort was the anti-leukaemia drug Mylotarg. Many more are either on the market or completing clinical trials. ... Times Online … cell transplantation for hemophagocytic lymphohistiocytosis: a... - Aug 4, 2008 Perhaps BU should be used in these individuals as cautiously as in those individuals who have previously received gemtuzumab ozogamicin (Mylotarg) or ... Nature.com Antibody–drug conjugates in acute myeloid leukemia - Jan 10, 2006 ...(2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence ... Nature.com PDL BioPharma Declares $500 Million Special Cash Dividend and … - Apr 10, 2008 Synagis® antibody product from MedImmune, Inc.; Tysabri® antibody product from Elan Pharmaceuticals, Inc.; and Mylotarg® antibody product from Wyeth. ... Lifescience-online Drug stocks trend positive but Maxygen hammered - Sep 21, 2007 It issued a negative opinion on Wyeth's Mylotarg for the re-induction treatment of CD33-positive acute myeloid leukaemia patients in first relapse who are ... MarketWatch The histone deacetylase inhibitor valproic acid potently augments … - Nov 23, 2006 The immunotoxin gemtuzumab ozogamicin (GO; Mylotarg) comprises a powerful tumoricidal calicheamicin derivative chemically linked to an antibody that ... Nature.com Press Release: ChemGenex Initiates New Phase 2 Trial of Ceflatonin(R)... - Oct 5, 2005 Article: Increased Use of Wyeth's Mylotarg and Launches of New Drugs Will ... PR Newswire; October 16, 2006 ; 700+ words ... ... double the market to treat ... Pay-Per-View - PR Newswire - HighBeam Research Use of physiological doses of human growth hormone in haematological ... - Dec 4, 2006 MACE 14, 15 (seven hGH, 10 placebo), DAT/DAM 15 (mylotarg with DA three hGH, eight placebo), UKALL XII/German ALL induction/consolidation 16 (four hGH, ... Nature.com Press Release: Wyeth Completes Purchase of Wyeth KK Japan. - PR … - Apr 3, 2007 Article: Japanese OK for Wyeth's Mylotarg.(Wyeth ... ... Wyeth Japan says that it has obtained approval for Mylotarg, a proprietary preparation of ... Pay-Per-View - PR Newswire - HighBeam Research Covering the Hudson to the Catskills! - Jul 22, 2008 Wyeth manufactures Prevnar infant pneumococcal vaccine, Mylotarg, which is used to treat bone marrow cancer, and Centrum vitamins. Mid-Hudson News FDA reviews status of cancer drugs - Nov 10, 2005 Mylotarg, from Wyeth Pharmaceuticals (down $0.39 to $44.26, Research), for the treatment of a specific type of relapsed leukemia in patients 60 or older who ... CNNMoney.com Antibody targeted drugs as cancer therapeutics - Nov 1, 2007 Of the discussed drugs, only Mylotarg, a chemotherapeutic drug conjugated to an antibody, has benn approved by the FDA so far. ... Nature.com Antibodies cut down to size - Aug 1, 2007 To date, only three toxified antibodies—Bexxar ( 131 I-anti-CD20; tositumomab), Mylotarg (anti-CD33-ozogamicin; gemtuzumab) and Zevalin ( 111 In-anti-CD20; ... Nature.com Antibodies : Sourcing guide : Nature - Sep 1, 2005 A presently marketed therapeutic of this nature, Mylotarg (gemtuzumab ozogamicin; Wyeth), is used to treat acute myelogenous leukaemia. ... Nature.com PDL to Spin Off Biotech Assets into New Firm by End of Year - Apr 14, 2008 Synagis antibody product from MedImmune Inc.; Tysabri antibody product from Elan Pharmaceuticals Inc.; and Mylotarg antibody product from Wyeth. ... BioWorld Online - BioWorld Online PDL taps Biogen Idec exec to oversee spinoff - Oct 3, 2008 MedImmune Inc.'s Synagis, Elan Pharmaceutical Inc.'s Tysabri and Wyeth Pharmaceutical's Mylotarg — compared to $221 million last year. ... San Francisco Business Times Cancer's costs | Article from The Record (Bergen County, NJ) |... - Apr 2, 2006 Drug: Mylotarg. Company: Wyeth. Treats: leukemia treatment for patients 60 and over. Cost: $12000 for an average treatment. ... Pay-Per-View - The Record - HighBeam Research St. Paul Pioneer Press : LIVER TESTS MANDATED TO AVOID SUDDEN … - Apr 13, 2005 ...gemfibrozil (Lopid), gemtuzumab (Mylotarg), griseofulvin (Gris-PEG), imatinib (Gleevec), indinavir (Crixivan), isoniazid, isotretinoin (Accutane), ... $2.95 - St. Paul Pioneer Press - NewsBank PDL BioPharma Announces Third Quarter 2006 Financial Results. - Nov 2, 2006 Herceptin(R), Xolair(R), Raptiva(R) and Lucentis(TM) from Genentech, Inc.; Synagis(R) from MedImmune, Inc. and Mylotarg(R) from Wyeth. ... Free with registration - PR Newswire - AccessMyLibrary.com PDL BioPharma Announces Second Quarter 2006 Financial Results. - Aug 3, 2006 Xolair(R) and Raptiva(R) from Genentech, Inc.; Synagis(R) from MedImmune, Inc. and Mylotarg(R) from Wyeth. -- License, collaboration and other revenues ... Free with registration - PR Newswire - AccessMyLibrary.com Correlation of CD33 with poorer prognosis in childhood ALL implicates... - Apr 14, 2005 High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. ... Nature.com The reason for those liver tests. - Mar 25, 2005 ...gemfibrozil (Lopid), gemtuzumab (Mylotarg), griseofulvin (Gris-PEG), imatinib (Gleevec), indinavir (Crixivan), isoniazid, isotretinoin (Accutane), ... Free with registration - Sun Herald - AccessMyLibrary.com סל הברי×?ות הב×?: 181 תרופות חדשות - Jan 31, 2005 ...avastin - לסרטן קולורקט×?לי גרורתי, erbitux - לסרטן קולורקט×?לי גרורתי, mylotarg - טיפול ב-aml. ... NRG מעריב انتشار أورام الدم والغدد اللمÙ?اوية Ù?ÙŠ المملكة بنسبة 25Ùª من مجم? - Jan 19, 2006 النخاعي المزمن وهذا العقار يثبط انزيم معين هو المسبب لهذا المرض، ومثل عقار MYLOTARG وهو ... الرياض Pharmion Presents Clinical Data Demonstrating Significant Survival … - Dec 9, 2007 25-II: 5-Azacytidine Augments the Cytotoxicity of Mylotarg toward AML Blasts In Vitro and In Vivo (Abstract # 1835). -- Poster Board No 39-II: Treatment of ... Free with registration - PR Newswire - AccessMyLibrary.com PDL Announces Third Quarter 2005 Financial Results. - Nov 1, 2005 Herceptin(R), Xolair(R) and Raptiva(R) from Genentech, Inc.; Synagis(R) from MedImmune, Inc.; Mylotarg(R) from Wyeth and Zenapax(R), marketed by Roche. ... Free with registration - PR Newswire - AccessMyLibrary.com Thomson Financial Business Description: - Jul 9, 2008 Erbitux (R) and Vectibix (R), two radionuclide-conjugated monoclonal antibodies Zevalin(R) and Bexxar (R) and an antibody-drug conjugate Mylotarg (R). ... Pay-Per-View - co - Alacra Store YM BIOSCIENCES NOTICE OF ANNUAL MEETING OF … - Oct 11, 2007 ...oncology compounds and contributed to the approval and commercialization of Mylotarg(R) for the treatment of a specific form of acute myeloid leukemia. ... Free with registration - PR Newswire - AccessMyLibrary.com ImClone Systems Names Philip Frost, MD, Ph.D., Chief Scientific... - Feb 15, 2005 ...the US Food and Drug Administration (FDA) approval and commercialization of Mylotarg (CMA-676); the filing of 15 patents and the issuance of 12 patents; ... RedOrbit INNOVIVE Pharmaceuticals Appoints Philip Frost, MD, Ph.D., to its... - Apr 30, 2007 ...oncology compounds and contributed to the approval and commercialization of Mylotarg(R) for the treatment of a specific form of acute myeloid leukemia. ... Genetic Engineering News - Genetic Engineering News (press release) Acceleron Pharma Appoints Matthew L. Sherman, MD as Chief Medical … - May 16, 2006 ...both small molecule and biologic therapeutics, including the submission and approval of Mylotarg(R) (gemtuzumab ozogamicin for injection) by the FDA. ... Free with registration - Business Wire - AccessMyLibrary.com Advances in Acute Myeloid Leukemia: An Interview With Jorge E.... - Mar 21, 2005 Gemtuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two ... Medscape Developing Sophisticated Protein-Based Drugs - Jul 1, 2005 This approach has proved difficult to realize in actuality, yet there are a number of conjugates in development or in clinical trials and one (Mylotarg) ... Genetic Engineering News - Genetic Engineering News (press release) United Kingdom, Litigation and Arbitration, Science Feature - … - Oct 8, 2006 ...medicine to powerful effect: the breast cancer drug Herceptin is a nanoscale antibody, and the anti-leukaemia drug Mylotarg is based on nanotechnology. ... Mondaq News Alerts - Mondaq News Alerts (Registration) Targeted Drugs - May 16, 2005 ...while PSMA is a solid cell cancer therapy. Wyeth's Mylotarg, a treatment for acute myeloid leukemia, is the only antibody-drug conjugate approved by FDA. Environmental Science & Technology How Is Acute Myeloid Leukemia Treated? - Sep 14, 2007 One such antibody (Mylotarg) has recently been approved for use in older adults with AML who have relapsed after treatment or who might not be able to take ... ACS News Center Asthma patient in funding wrangle - Jan 25, 2007 ...whose consultant had to appeal to the PCT's exceptional treatments group to get funding for the drug Mylotarg which is his best hope of recovery. ... Herts 24 Monoclonal antibodies as targeted cancer immunotherapeutics - Oct 6, 2005 For example, Mylotarg is a conjugate of mAb that binds to CD33, a cell-surface molecule expressed by cancerous cells but not generally found on normal stem ... expresspharmapulse.com Though early, Seattle Genetics' drugs show promise: analysts.(Importan... - May 1, 2006 Wyeth's marketed Mylotarg (gemtuzumab ozogamicin) for AML goes after the same target as SGN-33. Medarex Inc. has an anti-CD30 antibody in the works that ... Free with registration - Bioworld Financial Watch - AccessMyLibrary.com Event Brief of Q2 2005 Protein Design Earnings Conference Call -... - Aug 4, 2005 Mylotarg from Wyeth. 4. Zenapax marketed by Roche. 3. Expenses: 1. Total costs and expenses were $80.3m in 2Q05 vs. $39.5m in 2Q04. 2. On a non-GAAP basis, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Genentech asks ImmunoGen to devise scale-up - May 17, 2006 Nevertheless, manufacturing antibody-targeted chemotherapeutic agents on a commercial scale is not a novel task; Wyeth's gemtuzumab ozogamicin (Mylotarg), ... In-PharmaTechnologist.com PDL BioPharma Transforms into 'Biopharmaceutical' Innovator - Mar 14, 2006 Xolair and psoriasis treatment Raptiva (also developed by Berkeley's Xoma Ltd.), as well as MedImmune's Synagis, Wyeth's Mylotarg and Roche's Zenapax. ... RedOrbit Doxil Clinically Beneficial in Kaposi's Sarcoma - Nov 8, 2005 In addition to Doxil, the committee will review Genzyme's Campath, Pfizer's Celebrex, SkyePharma's DepoCyt, MedImmune's Ethyol, Wyeth's Mylotarg and ... RxPG NEWS Event Brief of Q3 2005 Protein Design Earnings Conference Call - Part... - Nov 1, 2005 PDLI also received royalties on Synagis from Medimmune, Mylotarg from Wyeth, and Zenapax, which is marketed by Roche. 6. License and other revenues ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Biotech blurring: big pharma has long looked to biotechs to help... - Oct 1, 2007 ...in notoriously tricky Japan within the same year--for Enbrel, on which it partnered with Takeda, and chemo agent Mylotarg for acute myeloid leukemia. ... Free with registration - Medical Marketing & Media - AccessMyLibrary.com The bigger picture: nanomedicines may be small-scale, but they offer ... - Jan 2, 2006 DaunoXome and Doxil/ Caelyx; antibodies derived therapeutics, for example, Herceptin and Avastin; and the first antibody-drug conjugate Mylotarg. ... Free with registration - Chemistry and Industry - AccessMyLibrary.com WYETH at SG Cowen & Co. 25th Annual Health Care Conference - … - Mar 15, 2005 Now, our small molecules, I mentioned some; Effexor, Rapamune, Protonix, Premarin and Zosyn; our biopharmaceuticals, Enbrel, ReFacto, InductOs and Mylotarg; ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Research Ethics Education offers tech-transfer lecture Dec. 7 - Dec 1, 2005 Taxol, Mylotarg and Tysabri, and the origination of the field of biotechnology with the licensing of the Cohen-Boyer patents on genetic engineering. ... Hutchinson Center A Life of Science Targeted and smart drugs for cancer: Dawn of a new era - Nov 12, 2007 These include Rituxan for non-Hodgkin's lymphoma; Herceptin for breast cancer; Mylotarg for acute myelogenous leukemia; Campath for chronic lymphocytic ... $2.95 - Oakland Tribune - NewsBank PDL BioPharma transforms into 'biopharmaceutical' innovator - Mar 13, 2006 Xolair and psoriasis treatment Raptiva (also developed by Berkeley's Xoma Ltd.), as well as MedImmune's Synagis, Wyeth's Mylotarg and Roche's Zenapax. ... $2.95 - Oakland Tribune - NewsBank PDL BioPharma Announces Fourth Quarter and Full Year 2005 Financial … - Feb 27, 2006 Herceptin(R), Xolair(R) and Raptiva(R) from Genentech, Inc.; Synagis(R) from MedImmune, Inc.; Mylotarg(R) from Wyeth and Zenapax(R), marketed by Roche. ... $4.95 - PR Newswire - ECNext Targeted therapy in leukemia - Dec 11, 2007 ...conjugated to the chemotherapy agent calicheamicin through a hydrazone linker to form the therapeutic agent known as gemtuzumab ozogamicin (Mylotarg). ... Nature.com High-potency APIs: containment and handling issues. - Sep 1, 2008 Wyeth's "Mylotarg" (gemtuzumab ozogamicin) is an example of such a drug. It is commercialized for treating acute myeloid leukemia, and numerous other ... $9.94 - Pharmaceutical Technology - Alacra Store PDL BioPharma Announces Fourth Quarter and Full Year 2006 Financial … - Feb 21, 2007 ...antibody product from MedImmune, Inc.; Tysabri(R) antibody product from Elan Pharmaceuticals, Inc.; and Mylotarg(R) antibody product from Wyeth. ... $4.95 - PR Newswire - ECNext Brand Names/Synonyms: Mylotarg is also known by the following brand names and/or synonymsMylotarg; anti-CD33; Mylotarg (Wyeth) Drug Category: Mylotarg is categorized under the following by the FDA: Antineoplastic Agents Dosage Forms: Not Available Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Humanized chimeric anti-CD33 antibody |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |